Overview of Dynamic Contrast-Enhanced MRI in Prostate Cancer Diagnosis and Management

Verma, Sadhna; Türkbey, Barış; Muradyan, Naira; Arora, Rajesh; Cornud, F.; Haider, Masoom A.; Choyke, Peter L.; Harisinghani, Mukesh G.

doi:10.2214/ajr.12.8510

Cited by 267 publications

(262 citation statements)

References 64 publications

Supporting

Mentioning

234

Contrasting

Unclassified

Order By: Relevance

“…A sensitivity of 55-88% and 46-90% and a specificity of 67-82% and 74-96% were reported by different authors for T2WI and DCE-MRI, respectively. [8][9][10] The introduction of diffusion-weighted imaging (DWI) by measurement of the restriction of water diffusion of suspicious lesions has significantly improved the detection and localization of PCa in clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Biparametric MRI of the prostate

Scialpi

D’Andrea

Martorana

et al. 2017

Turkish Journal of Urology

View full text Add to dashboard Cite

Biparametric Magnetic Resonance Imaging (bpMRI) of the prostate combining both morphologic T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI) is emerging as an alternative to multiparametric MRI (mpMRI) to detect, to localize and to guide prostatic targeted biopsy in patients with suspicious prostate cancer (PCa). BpMRI overcomes some limitations of mpMRI such as the costs, the time required to perform the study, the use of gadolinium-based contrast agents and the lack of a guidance for management of score 3 lesions equivocal for significant PCa. In our experience the optimal and similar clinical results of the bpMRI in comparison to mpMRI are essentially related to the DWI that we consider the dominant sequence for detection suspicious PCa both in transition and in peripheral zone. In clinical practice, the adoption of bpMRI standardized scoring system, indicating the likelihood to diagnose a clinically significant PCa and establishing the management of each suspicious category (from 1 to 4), could represent the rationale to simplify and to improve the current interpretation of mpMRI based on Prostate Imaging and Reporting Archiving Data System version 2 (PI-RADS v2). In this review article we report and describe the current knowledge about bpMRI in the detection of suspicious PCa and a simplified PI-RADS based on bpMRI for management of each suspicious PCa categories to facilitate the communication between radiologists and urologists.

show abstract

Section: Introductionmentioning

confidence: 99%

Biparametric MRI of the prostate

Scialpi

D’Andrea

Martorana

et al. 2017

Turkish Journal of Urology

View full text Add to dashboard Cite

show abstract

“…[12] Because of the detection of neovascularization in the tissue, it is particularly useful in locating recurrence after surgical treatment. [16,22] However, due to neovascularity, it may also give false positive results, especially in cases of inflammation. [23] In addition, the operation lasts longer.…”

Section: Multiparametric Mri Sequencesmentioning

confidence: 99%

Multiparametric magnetic resonance imaging: Overview of the technique, clinical applications in prostate biopsy and future directions

Demirel

Davis

2018

Turkish Journal of Urology

View full text Add to dashboard Cite

Multiparametric magnetic resonance imaging (mpMRI) has managed to change the paradigms on prostate cancer detection and risk classification. The most clear-cut indication of mpMRI in guidelines is the patients with a history of negative biopsy/increasing prostate-specific antigen (PSA), and presence of additional findings supporting its use in non biopsied patients and active surveillance. mpMRI complements standard clinical exam, PSA measurements, and systematic biopsy, and will miss some tumors that lack enough size or change in tissue density. Use of mpMRI is likely to increase, and further developments in the technique will be important for safe adoption of focal therapy concepts. Here we present a brief summary about mpMRI and its use in detection, risk classification and follow-up of prostate cancer.

show abstract

“…33 Due to neovascularization, cancerous tissue will typically show early enhancement and washout compared to that of adjacent healthy tissue. DCE images can be evaluated visually or by enhancement curve type analysis.…”

Section: Dcementioning

confidence: 99%

Spotlight on multiparametric magnetic resonance imaging in prostate cancer management: current perspectives

Hassanzadeh¹,

Tempany²

2016

RMI

View full text Add to dashboard Cite

Clinical behavior of prostate cancer, the most common noncutaneous cancer in men, ranges from a nonsignificant indolent tumor to an aggressive cancer. Prostate cancer is subject to overdiagnosis and overtreatment, making screening, diagnosis, and treatment planning a controversial issue. Recently, even noninvasive simple screening methods such as prostatespecific antigen level and digital rectal examination are no longer recommended for screening as it has resulted in no reduction in mortality. Diagnosis and further treatment planning, however, are still based on a random transrectal ultrasound-guided biopsy, an invasive method with controversial efficacy that has been deemed as unnecessarily revealing nonsignificant tumors. Magnetic resonance (MR)-based techniques are emerging that provide noninvasive tools that are promising in the detection of clinically significant lesions and accurate staging. Moreover, MR imaging improves the performance of image-guided procedures, both in diagnosis and therapy. We focus here on recent advances in multiparametric MR imaging in prostate cancer diagnosis and provide a brief overview of other emerging techniques.

show abstract

Overview of Dynamic Contrast-Enhanced MRI in Prostate Cancer Diagnosis and Management

Cited by 267 publications

References 64 publications

Biparametric MRI of the prostate

Biparametric MRI of the prostate

Multiparametric magnetic resonance imaging: Overview of the technique, clinical applications in prostate biopsy and future directions

Spotlight on multiparametric magnetic resonance imaging in prostate cancer management: current perspectives

Contact Info

Product

Resources

About